Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

N0850000

Nimodipine

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester, Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H26N2O7
Número de CAS:
66085-59-4
Peso molecular:
418.44
MDL number:
MFCD00153848
UNSPSC Code:
41116107
PubChem Substance ID:
329818466
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nimodipine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COCCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC(C)C

InChI

1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

InChI key

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779) , NR3C2(4306)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nimodipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

N0850010

Nimodipine impurity A, European Pharmacopoeia (EP) Reference Standard

1463870

Nimodipine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463858

Nimodipine, United States Pharmacopeia (USP) Reference Standard

1463869

Nimodipine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001784

Nimodipine for peak identification, European Pharmacopoeia (EP) Reference Standard

BP651

Nimodipine, British Pharmacopoeia (BP) Reference Standard

75161

Bis(1-methylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

BP943

Nimodipine impurity A, British Pharmacopoeia (BP) Reference Standard

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

W Mück et al.
Die Pharmazie, 49(2-3), 130-139 (1994-02-01)
The analytical test procedures currently established for the determination of the dihydropyridine calcium antagonist nimodipine in biological fluids are presented. Method of choice which has been dominantly used in pharmacokinetic investigations and drug interaction studies is gas chromatography with electron-capture
J Horn et al.
Stroke, 32(10), 2433-2438 (2001-10-06)
Based on the results of animal experiments, clinical trials were performed with nimodipine, which did not demonstrate a beneficial effect on outcome after stroke. The aim of this study was to determine whether the evidence from animal experiments with nimodipine
Potential interactions between nimodipine and adrenal hormones.
R L Isaacson et al.
Annals of the New York Academy of Sciences, 765, 134-142 (1995-09-15)
Mervyn D I Vergouwen et al.
The Lancet. Neurology, 5(12), 1029-1032 (2006-11-18)
Despite several randomised controlled trials, there is still much debate whether nimodipine improves outcome in patients with traumatic subarachnoid haemorrhage. A 2003 Cochrane review reported improved outcome with nimodipine in these patients; however, because the results of Head Injury Trial
Daniele Tomassoni et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 30(8), 744-766 (2008-11-21)
Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. It is highly lipophilic, crosses the blood-brain barrier, and reaches brain and cerebrospinal fluid. Early treatment with nimodipine reduces the severity of neurological deficits resulting from vasospasm in subarachnoid
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico